TY - JOUR AU - SIDNEY, KAMILA MARIA MARANHÃO AU - ROMEU, GEYSA AGUIAR AU - PINHEIRO, CESAR GOMES PY - 2019/03/11 Y2 - 2024/03/29 TI - Study of adverse reactions to paclitaxel in patients with breast cancer in a reference hospital JF - Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde JA - Rev Bras Farm Hosp Serv Saude VL - 8 IS - 1 SE - ARTIGOS PUBLICADOS DO - UR - https://rbfhss.org.br/sbrafh/article/view/278 SP - AB - <div>o study the adverse reactions observed in patients with breast cancer in treatment with Paclitaxel. Observational, prospective and quantitative type of study, with 24 users with non-metastatic breast cancer treated with Paclitaxel, at a reference hospital in cancer in Fortaleza-Ceará. The variables used were:</div><div>social profile; dose of the medicine for body surface; infusion speed; suspect of adverse reaction immediate and late. Data were analyzed with the statistical program Epi Info version 3.5.4. The middle age was of 51.2 years (± 13 years). It was observed that the first pregnancy of 62.5% of patients occurred until</div><div>their 30 years; that 70.8% breastfed for at least six months; that 58.3% stated have not used oral contraceptive; and that 58.3% had diagnosis of cancer between six months and a year before treatment. Presented adverse reactions to infusion of Paclitaxel 12.5% of patients, 71.4% of whom described in bula,</div><div>66.6% classified as moderate and 71.4% as likely to occurs, and all evolved with recovery. Patients (87.5%) reported bitter mouth, headache constipation, and abdominal pain, late adverse reactions, some not described in the drug labeling. The disease incidence was observed even in users who did not use</div><div>contraceptives and breastfed, protected, according to the literature, against the occurrence of breast cancer. Ocular hyperemia and bitter mouth, new adverse reactions identified, stimulate the investigation of adverse events.</div> ER -